Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13018929 | 0.82 | ALDH1A1 (0.45) | ALDH1A1NPSR1CPB2SMN1; SMN2 | |
| SCHEMBL17229260 | 0.80 | CYP2A6 (0.34) | S1PR1S1PR3CPB1CPB2SMN1; SMN2 | |
| SCHEMBL21503664 | 0.79 | ALDH1A1 (0.33) | ALDH1A1NPSR1CPB2SMN1; SMN2ESR1 | |
| SCHEMBL9998961 | 0.79 | KCNJ5 (0.38) | — | |
| SCHEMBL9998965 | 0.79 | KCNJ5 (0.38) | — | |
| SCHEMBL2597202 | 0.78 | NOS3 (0.35) | ALDH1A1NPSR1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1912419 | 0.78 | ALDH1A1 (0.41) | ALDH1A1NPSR1SMN1; SMN2CHRNB2CHRNB4 | |
| SCHEMBL17229318 | 0.77 | CHRNB2 (0.37) | ALDH1A1NPSR1CPB2SMN1; SMN2CHRNB2 | |
| SCHEMBL17229282 | 0.77 | S1PR1 (0.33) | S1PR1S1PR3CPB1CPB2SMN1; SMN2 | |
| SCHEMBL26138262 | 0.77 | S1PR1 (0.33) | S1PR1S1PR3CPB1CPB2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2015171527-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | ALDH1A1 416/4885NPSR1 3309/4885S1PR1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.